SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.

A group of researchers from Japan's University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center said ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The Veterinary officers in the Keta Municipality of the Volta Region have destroyed over 500 affected chickens in a poultry farm at Abor to prevent the spread of avian influenza in the area. The move, ...

The first and most widely used single-dose antiviral flu pill is baloxavir marboxil, marketed as Xofluza and developed by the global pharmaceutical giant Roche. It was first approved in China in April ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and should even be effective against new strains ...

Background The large-scale deployment of antiviral drugs from the Strategic National Stockpile during the 2009 H1N1 influenza response provides a unique opportunity to study local public health ...